White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging

Journal of Rheumatology

Volumn 37, Issue 5, 2010, Pages 974-986

  Xu, Jian ^a,b,c   Cheng, Yuqi ^b,c,d   Chai, Pei ^e   Lu, Zhaoping ^c   Li, Haijun ^f   Luo, Chunrong ^f   Li, Xizhi ^c   Li, Lin ^e   Zhou, Qixin ^d   Chen, Bing ^a   Cao, Jun ^d   Xu, Xiufeng ^c   Shan, Baoci ^e   Xu, Lin ^d   Wen, Jianfan ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^e INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^f First Hospital of Kunming City   (China)

Author keywords

Immunosuppressive therapy; Magnetic resonance imaging; Systemic lupus erythematosus; White matter

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN INJURY; BRAIN PROTECTION; BRAIN SIZE; CAPSULA INTERNA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORPHOMETRICS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPORAL LOBE; TREATMENT OUTCOME; TREATMENT RESPONSE; WHITE MATTER;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951842482     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090967     Document Type: Article

References (58)

1. Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 2000;9:573-583
2. Adelman DC, Saltiel E, Klinenberg JR. The neuropsychiatric manifestations of systemic lupus erythematosus: an overview. Semin Arthritis Rheum 1986;15:185-199 (Pubitemid 16132227)
3. Navarrete MG, Brey RL. Neuropsychiatric systemic lupus erythematosus. Curr Treat Options Neurol 2000;2:473-485
4. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 1976;55:323-339
5. Kozora E, Arciniegas DB, Filley CM, West SG, Brown M, Miller D, et al. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum 2008;59:1639-1646
6. Bosma GP, Middelkoop HA, Rood MJ, Bollen EL, Huizinga TW, van Buchem MA. Association of global brain damage and clinical functioning in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2002;46:2665-2672
7. Hughes M, Sundgren PC, Fan X, Foerster B, Nan B, Welsh RC, et al. Diffusion tensor imaging in patients with acute onset of neuropsychiatric systemic lupus erythematosus: a prospective study of apparent diffusion coefficient, fractional anisotropy values, and eigenvalues in different regions of the brain. Acta Radiol 2007;48:213-222 (Pubitemid 46396995)
8. Sibbitt WL Jr, Sibbitt RR, Griffey RH, Eckel C, Bankhurst AD. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis 1989;48:1014-1022 (Pubitemid 20014805)
9. Huizinga TW, Steens SC, van Buchem MA. Imaging modalities in central nervous system systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:383-388 (Pubitemid 32929867)
10. Cotton F, Bouffard-Vercelli J, Hermier M, Tebib J, Vital Durand D, Tran Minh VA, et al. MRI of central nervous system in a series of 58 systemic lupus erythematosus (SLE) patients with or without overt neuropsychiatric manifestations. Rev Med Intern 2004;25:8-15. (Pubitemid 38229163)
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
12. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-813 (Pubitemid 27199995)
13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
17. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9:97-113.
18. Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005;52:2783-2789 (Pubitemid 41369107)
19. Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allerg Immunol 2008;34:361-366
20. Brey RL. Neuropsychiatric lupus: clinical and imaging aspects. Bull NYU Hosp Joint Dis 2007;65:194-199 (Pubitemid 351412132)
21. Kozora E, Arciniegas DB, Filley CM, Ellison MC, West SG, Brown MS, et al. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 2005;18:159-162
22. Falcini F, De Cristofaro MT, Ermini M, Guarnieri M, Massai G, Olmastroni M, et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: A prospective SPECT study. Single photon emission computed tomography. J Rheumatol 1998;25:583-588
23. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000;11:805-821
24. Rotzer S, Kucian K, Martin E, von Aster M, Klaver P, Loenneker T. Optimized voxel-based morphometry in children with developmental dyscalculia. Neuroimage 2008;39:417-422 (Pubitemid 350102223)
25. Kennedy KM, Erickson KI, Rodrigue KM, Voss MW, Colcombe SJ, Kramer AF, et al. Age-related differences in regional brain volumes: A comparison of optimized voxel-based morphometry to manual volumetry. Neurobiol Aging 2009;30:1657-1676
26. Appenzeller S, Amorim BJ, Ramos CD, Rio PA, de C Etchebehere EC, Camargo EE, et al. Voxel-based morphometry of brain SPECT can detect the presence of active central nervous system involvement in systemic lupus erythematosus. Rheumatology 2007;46:467-472 (Pubitemid 46344660)
27. Appenzeller S, Bonilha L, Rio PA, Min Li L, Costallat LT, Cendes F. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage 2007;34:694-701. (Pubitemid 44827765)
28. Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol 2008;35:2348-2354
29. Pay RG. Control of complex conation and emotion in the neocortex by the limbic entorhinal, subicular, and cingulate cortices and the hypothalamus, mammillary body, and thalamus. Int J Neurosci 1981;15:1-30.
30. Fernstrom JD. Effects of precursors on brain neurotransmitter synthesis and brain functions. Diabetologia 1981;20 Suppl:281-289
31. Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986;174:357-364 (Pubitemid 16084918)
32. Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992;19:562-567
33. Wekking EM, Nossent JC, van Dam AP, Swaak AJ. Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother Psychosom 1991;55:126-131
34. Gao HX, Campbell SR, Cui MH, Zong P, Hee-Hwang J, Gulinello M, et al. Depression is an early disease manifestation in lupus-prone MRL/lpr mice. J Neuroimmunol 2009;207:45-56.
35. Rudofsky UH, Evans BD, Balaban SL, Mottironi VD, Gabrielsen AE. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest 1993;68:419-426
36. Rudofsky UH, Lawrence DA. New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environ Health Perspect 1999;107 Suppl 5:713-721
37. Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, et al. Cognition and immunity; antibody impairs memory. Immunity 2004;21:179-188 (Pubitemid 39094048)
38. Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res 2002;16:229-244 (Pubitemid 36526641)
39. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
40. Leung FK, Fortin PR. Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. J Rheumatol 2003;30:1871-1873
41. Shahani N, Gourie-Devi M, Nalini A, Raju TR. Cyclophosphamide attenuates the degenerative changes induced by CSF from patients with amyotrophic lateral sclerosis in the neonatal rat spinal cord. J Neurol Sci 2001;185:109-118 (Pubitemid 32318515)
42. Tajti J, Stefani E, Appel SH. Cyclophosphamide alters the clinical and pathological expression of experimental autoimmune gray matter disease. J Neuroimmunol 1991;34:143-151
43. Baum KA, Hopf U, Nehrig C, Stover M, Schorner W. Systemic lupus erythematosus: neuropsychiatric signs and symptoms related to cerebral MRI findings. Clin Neurol Neurosurg 1993;95:29-34. (Pubitemid 23090699)
44. Hachulla E, Michon-Pasturel U, Leys D, Pruvo JP, Queyrel V, Masy E, et al. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies. Lupus 1998;7:124-131 (Pubitemid 28107978)
45. Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 2008;64:635-643
46. Steens SC, Bosma GP, Steup-Beekman GM, le Cessie S, Huizinga TW, van Buchem MA. Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus. Arthritis Res Ther 2006;8:R38.
47. Baraczka K, Nekam K, Pozsonyi T, Szuts I, Ormos G. Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur J Neurol 2004;11:37-42. (Pubitemid 38174920)
48. Abbott NJ, Mendonca LL, Dolman DE. The blood-brain barrier in systemic lupus erythematosus. Lupus 2003;12:908-915 (Pubitemid 38082086)
49. Ikenouchi-Sugita A, Yoshimura R, Ueda N, Kodama Y, Umene-Nakano W, Nakamura J. Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes. Neuropsychiatr Dis Treat 2008;4:1277-1281
50. Lockshin MD. Antiphospholipid antibody: future developments. Lupus 1994;3:309-311
51. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003;30:985-992 (Pubitemid 36529618)
52. Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998;29:2254-2260 (Pubitemid 28511941)
53. Zhang X, Shu H, Zhang F, Tian X, Dong Y. Cell-ELISA detection of antineuronal antibodies in central nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 2007;66:530-532 (Pubitemid 46580476)
54. How A, Dent PB, Liao SK, Denburg JA. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1985;28:789-795 (Pubitemid 15027333)
55. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006;54:2505-2514 (Pubitemid 44205011)
56. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006;33:1553-1558 (Pubitemid 44168826)
57. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006;54:2515-2522 (Pubitemid 44205012)
58. Chinn RJ, Wilkinson ID, Hall-Craggs MA, Paley MN, Shortall E, Carter S, et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:36-46. (Pubitemid 27044034)